Insight Molecular Diagnostics
IMDX
88 hedge funds and large institutions have $120M invested in Insight Molecular Diagnostics in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 17 closing their positions.
611% more call options, than puts
Call options by funds: $626K | Put options by funds: $88K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.08% less ownership
Funds ownership: 3.09% → 3.01% (-0.08%)
10% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 31
7% less funds holding
Funds holding: 95 → 88 (-7)
35% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 17
40% less capital invested
Capital invested by funds: $201M → $120M (-$81.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$1.83M |
| 2 |
BlackRock
New York
|
+$1.8M |
| 3 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$736K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$726K |
| 5 |
Morgan Stanley
New York
|
+$466K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$2.78M |
| 2 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$2.19M |
| 3 |
AIC
AWM Investment Company
New York
|
-$1.37M |
| 4 |
Two Sigma Investments
New York
|
-$1.12M |
| 5 |
Two Sigma Advisers
New York
|
-$1.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
101
Parallel Advisors
San Francisco,
California
| – | -$1K | -11 | Closed |
|
|
LC
102
Lindbrook Capital
Calabasas,
California
| – | -$345 | -6 | -60% |
|
103
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$288 | +5 | New |
|
|
CI
104
Carroll Investors
Mt Pleasant,
South Carolina
| – | +$863 | +15 | New |
|
IMDX Hedge Fund Activity: Q4 2021 in Review
88 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q4 2021, worth a combined $120M — down 40% from $201M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IMDX and 11 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 28 added.
The largest buyer was OrbiMed, adding an estimated $1.83M. The largest seller was GW&K Investment Management, exiting entirely with an estimated $2.78M sold.
- 88 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q4 2021, down from 95 in Q3 2021.
- Funds reported $120M of Insight Molecular Diagnostics stock for Q4 2021, down 40% quarter-over-quarter.
- 11 funds opened new Insight Molecular Diagnostics positions in Q4 2021 and 17 closed out, a net change of -6 holders.
- The largest Insight Molecular Diagnostics buyer in Q4 2021 was OrbiMed, an estimated $1.83M added.
- The largest Insight Molecular Diagnostics seller in Q4 2021 was GW&K Investment Management, an estimated $2.78M sold.
Based on aggregated 13F filings for Q4 2021.